Combination Insulin Therapy with Pre-Mixed Intermediate/Rapid-Acting Insulin (70/30) and Insulin Lispro Mimicking Physiologic Insulin Secretion: Optimal Glycemic Treatment with Systainability of Control in Type 2 Diabetic Patients

Abstract

Methods: In this descriptive retrospective study, we measured glycemic control and sustainability in terms of reduction in HbA1c and postprandial capillary blood glucose (pCBG) between patients on insulin 70/30 with lispro and insulin 70/30 alone. We reviewed records of 218 patients (153 females; 65 males) in an outpatient endocrinology clinic. Initial and follow-up pCBG (2 to 4 hours after lunch) and HbA1c were measured and compared among study groups. Metformin 1000 to 1500 mg daily was given in combination with insulin.